Literature DB >> 9492049

Activin regulates betaA-subunit and activin receptor messenger ribonucleic acid and cellular proliferation in activin-responsive testicular tumor cells.

N Di Simone1, H A Hall, C Welt, A L Schneyer.   

Abstract

Activin, a member of the transforming growth factor-beta superfamily of growth and differentiation factors, has a number of actions in embryonic as well as adult tissues. These actions are mediated via a family of receptors containing two subtypes and at least two members of each subtype. Recent evidence demonstrates that activin-responsive cell lines containing different subsets of these receptors are valuable models for dissecting functional relationships among receptor subtype, signal transduced, and response obtained. TT cells, derived from a p53(-/-)/alpha-inhibin(-/-) mouse testicular tumor, respond to activin by proliferating, a response that can be inhibited by follistatin (FS) treatment. Using semiquantitative RT-PCR methods, we characterized steady state messenger RNA (mRNA) levels for the inhibin/activin subunits, FS, and activin receptor subtypes under basal conditions and in the presence of activin or FS. These cells produced ample immunoreactive activin A and FS, necessitating higher treatment doses to observe any modulation of cellular proliferation. Furthermore, in the presence of exogenous activin, mRNA levels for activin receptor type IIA (ACTRIIA) and betaA were significantly and profoundly suppressed. In addition, both ACTR1B and ACTRIIB were detectable and down-regulated by exogenous activin, although not to the degree observed for ACTRIIA and betaA. Finally, activin treatment at the higher doses, which decreased activin receptor mRNA levels, resulted in inhibition of cellular proliferation. Taken together with previous observations, our results support the model that these tumor cells respond to an autocrine activin signal by proliferating, whereas exogenous or excess activin results in down-regulation of activin receptor and activin biosynthesis, suggesting a potential autocrine/paracrine mechanism by which activin can modulate its own signal.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9492049     DOI: 10.1210/endo.139.3.5800

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  4 in total

1.  Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease.

Authors:  Olga A Agapova; Yifu Fang; Toshifumi Sugatani; Michael E Seifert; Keith A Hruska
Journal:  Kidney Int       Date:  2016-03-11       Impact factor: 10.612

2.  Directed differentiation of human embryonic stem cells towards a pancreatic cell fate.

Authors:  J H Shim; S E Kim; D H Woo; S K Kim; C H Oh; R McKay; J H Kim
Journal:  Diabetologia       Date:  2007-04-18       Impact factor: 10.122

3.  Activin-A up-regulates type I activin receptor mRNA levels in human immortalized extravillous trophoblast cells.

Authors:  Victor T S Chen; Chun Peng; Peter C K Leung
Journal:  Reprod Biol Endocrinol       Date:  2003-03-24       Impact factor: 5.211

4.  Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects.

Authors:  Xingyi Guo; Weiqiang Lin; Wanqing Wen; Jeroen Huyghe; Stephanie Bien; Qiuyin Cai; Tabitha Harrison; Zhishan Chen; Conghui Qu; Jiandong Bao; Jirong Long; Yuan Yuan; Fangqin Wang; Mengqiu Bai; Goncalo R Abecasis; Demetrius Albanes; Sonja I Berndt; Stéphane Bézieau; D Timothy Bishop; Hermann Brenner; Stephan Buch; Andrea Burnett-Hartman; Peter T Campbell; Sergi Castellví-Bel; Andrew T Chan; Jenny Chang-Claude; Stephen J Chanock; Sang Hee Cho; David V Conti; Albert de la Chapelle; Edith J M Feskens; Steven J Gallinger; Graham G Giles; Phyllis J Goodman; Andrea Gsur; Mark Guinter; Marc J Gunter; Jochen Hampe; Heather Hampel; Richard B Hayes; Michael Hoffmeister; Ellen Kampman; Hyun Min Kang; Temitope O Keku; Hyeong Rok Kim; Loic Le Marchand; Soo Chin Lee; Christopher I Li; Li Li; Annika Lindblom; Noralane Lindor; Roger L Milne; Victor Moreno; Neil Murphy; Polly A Newcomb; Deborah A Nickerson; Kenneth Offit; Rachel Pearlman; Paul D P Pharoah; Elizabeth A Platz; John D Potter; Gad Rennert; Lori C Sakoda; Clemens Schafmayer; Stephanie L Schmit; Robert E Schoen; Fredrick R Schumacher; Martha L Slattery; Yu-Ru Su; Catherine M Tangen; Cornelia M Ulrich; Franzel J B van Duijnhoven; Bethany Van Guelpen; Kala Visvanathan; Pavel Vodicka; Ludmila Vodickova; Veronika Vymetalkova; Xiaoliang Wang; Emily White; Alicja Wolk; Michael O Woods; Graham Casey; Li Hsu; Mark A Jenkins; Stephen B Gruber; Ulrike Peters; Wei Zheng
Journal:  Gastroenterology       Date:  2020-10-12       Impact factor: 33.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.